RPI ID: 2017-059-402

Innovation Summary:
This invention introduces a novel biosensing platform for the multiplex detection of bacterial pathogens using engineered cell wall binding domain (CBD) complexes. These complexes selectively bind to bacterial cell walls and are conjugated with distinct reporter molecules, enabling simultaneous detection of multiple bacterial species in a single assay. The system offers high specificity, rapid response, and adaptability to various detection formats, including fluorescence and colorimetric readouts. This approach is well-suited for clinical diagnostics, food safety, and environmental monitoring.

Challenges / Opportunities:
Traditional bacterial detection methods often require time-consuming culturing or complex molecular assays, which can delay diagnosis and increase costs. This invention addresses those limitations by offering a rapid, multiplexed detection system that does not rely on nucleic acid amplification or antibody-based recognition. It opens opportunities for point-of-care diagnostics, high-throughput screening, and field-deployable biosensors.

Key Benefits / Advantages:
✔ Simultaneous detection of multiple bacterial species
✔ High specificity via engineered CBD targeting
✔ Rapid, label-based detection (fluorescent or colorimetric)
✔ Scalable for clinical, food, and environmental applications
✔ No need for PCR or antibody reagents

Applications:
• Clinical diagnostics for bacterial infections
• Food safety and contamination screening
• Environmental pathogen monitoring
• Point-of-care and field diagnostics
• Biothreat detection

Keywords:
#bacterialdetection #CBDcomplexes #biosensor #multiplexassay #pathogendiagnostics #rapiddetection

Intellectual Property:
US Issued Patent 12,099,057 B2